摘要
目的探究重组人生长激素对于Gn RHa治疗中生长过度减速的特发性中枢性性早熟女孩的临床效果,并分析CPP女孩的FAH的影响。方法将该院2002年12月—2015年12月期间所收治的46例特发性中枢性性早熟女孩作为该研究对象,所有女孩均接受Gn RHa(性腺激素释放激素激动剂)治疗,若女孩身高的增长速度减慢,程度为每年4 cm以下时,对其进行分组治疗,将联用重组人生长激素治疗的23例女孩归为联用组,而拒绝应用重组人生长激素治疗的23例女孩归为单用组,对比分析两组治疗后的PAH与FAH。结果联用组(n=23)性腺激素释放激素激动剂治疗后升高增长速度逐渐减慢,生长过度减速为每年4 cm以下,平均减速为(3.1±1.0)cm/年,在经重组人生长激素治疗后升高增长速度明显增加为(6.6±1.9)cm/年,联用组生长激素治疗结束时HA与BA的比值为(2.26±1.85),治疗前(0.03±0.03),治疗前后差异有统计学意义(P<0.05)。联用组生长激素治疗前骨龄与年龄增长的比值为(0.5±0.4),治疗后(0.6±0.3),差异无统计学意义(P>0.05)。治疗结束时,联合组成年身高的改善为(9.3±5.0)cm,单用组(4.1±4.0)cm,联用组身高改善程度明显高于单用组,两组差异有统计学意义。结论联用重组人生长激素能够有效加快性腺激素释放激素激动剂治疗中生长过度减速的特发性中枢性性早熟女孩的身高增长速度,且在改善预测成年身高与最终成年身高方面存在明显优势。
Objective To study the clinical effect of chondrotropic hormone in idiopathic central precocious puberty girls with overgrowth deceleration in Gn RHa treatment and analyze the FAH effect of CPP girls. Methods 46 cases of idiopathic central precocious puberty girls admitted and treated in our hospital from December 2002 to December 2015 were selected and all girls received the Gn RHa treatment, if the growth speed of height of girls slowed down, less than4 cm every year, they were divided into two groups with 23 cases in each, the combined group used the recombinant human growth hormone, the single group refused the recombinant human growth hormone, and the PAH and FAH of the two groups after treatment were compared and analyzed. Results Before treatment, the growth speed became slow, and when the overgrowth deceleration was below 4cm, the average deceleration was(3.1±1.0)cm every year, after rh GH treatment,the growth speed obviously increased to(6.6±1.9) cm every year, and the ratio of HA and BA was(2.26±1.85)at the end of treatment in the combined group and(0.03±0.03)before treatment, and the difference before and after treatment was obvious with statistical significance(P<0.05), in the combined group, the ratio of bone age and age increase before treatment and after treatment was respectively(0.5±0.4)and(0.6±0.3), and the difference was not obvious without statistical significance(P>0.05), at the end of treatment, the adult height increased to(9.3±5.0)cm in the combined group and(4.1±4.0)cm in the single group, and the difference was obvious with statistical significance. Conclusion The rh GH can effectively accelerate the height growth speed of idiopathic central precocious puberty girls with overgrowth deceleration in Gn RHa treatment and have an obvious advantage in improving the predictive adult height and final adult height.
出处
《系统医学》
2017年第10期86-88,共3页
Systems Medicine
